Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COPD: clinical phenotypes.

Thomas L Petty1

  • 1University of Colorado Health Sciences, NLHEP, 1850 High Street, Denver, CO 80218, USA. tlpdoc@aol.com

Pulmonary Pharmacology & Therapeutics
|September 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CO<sub>2</sub> Can Be Good for You.

Chest·2021
Same author

Staying Active With COPD.

The Physician and sportsmedicine·2017
Same author

Physiologic evaluation of bronchial asthma.

Postgraduate medicine·2017
Same author

Five-year outcome of lung cancer detection in patients with and without airflow obstruction in a primary care outpatient practice.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2009
Same author

Will recommendations against spirometry make chronic obstructive pulmonary disease harder to treat?

Annals of internal medicine·2008
Same author

The history of COPD.

International journal of chronic obstructive pulmonary disease·2007
Same journal

Brain-derived neurotrophic factor (BDNF) signaling in respiratory disease: Mechanisms, neuroimmune crosstalk, and therapeutic implications.

Pulmonary pharmacology & therapeutics·2026
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Chronic obstructive pulmonary disease (COPD) presents differently in early stages, often without symptoms. Advanced COPD phenotypes are less common due to effective therapies.

Area of Science:

  • Pulmonary Medicine
  • Respiratory Disease Research

Background:

  • Chronic obstructive pulmonary disease (COPD) management has evolved, impacting disease presentation.
  • Early-stage COPD is frequently asymptomatic, complicating diagnosis and intervention.

Observation:

  • COPD can manifest with various phenotypes, including asthma, chronic bronchitis, and emphysema, particularly in early or undiagnosed stages.
  • Uncommon presentations of COPD in younger individuals can be severe and dramatic.

Findings:

  • Therapeutic interventions have reduced the prevalence of diverse phenotypic presentations in advanced COPD.
  • Early COPD may mimic other respiratory conditions, necessitating careful differential diagnosis.

Implications:

  • Understanding early COPD phenotypes is crucial for timely diagnosis and treatment initiation.

Related Experiment Videos

  • The impact of modern therapies on COPD presentation warrants continued investigation.